Immunovant (IMVT) Projected to Release Quarterly Earnings on Thursday

Immunovant (NASDAQ:IMVT) is expected to be posting its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect Immunovant to announce earnings of ($0.6289) per share for the quarter. Interested persons may review the information on the company’s upcoming Q1 2027 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Immunovant (NASDAQ:IMVT) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.13). During the same period in the prior year, the firm posted ($0.64) earnings per share. On average, analysts expect Immunovant to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunovant Price Performance

Shares of IMVT stock opened at $39.36 on Wednesday. Immunovant has a 1 year low of $14.32 and a 1 year high of $41.23. The stock’s 50 day simple moving average is $36.85 and its two-hundred day simple moving average is $30.33. The company has a market cap of $8.12 billion, a PE ratio of -14.16 and a beta of 0.77.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. HC Wainwright increased their price target on Immunovant from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Bank of America boosted their price objective on shares of Immunovant from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Guggenheim increased their target price on shares of Immunovant from $44.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Truist Financial raised their target price on shares of Immunovant from $23.00 to $30.00 and gave the stock a “hold” rating in a report on Friday, May 22nd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Immunovant from $47.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Immunovant has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Insiders Place Their Bets

In other news, Director Atul Pande sold 1,500 shares of Immunovant stock in a transaction on Friday, June 26th. The stock was sold at an average price of $38.01, for a total transaction of $57,015.00. Following the completion of the sale, the director directly owned 116,731 shares in the company, valued at approximately $4,436,945.31. This trade represents a 1.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Tuyl Christopher Van sold 1,206 shares of Immunovant stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $39.55, for a total value of $47,697.30. Following the sale, the insider owned 179,391 shares of the company’s stock, valued at approximately $7,094,914.05. This trade represents a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 324,810 shares of company stock valued at $11,350,166. Insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Immunovant

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its stake in Immunovant by 16.0% in the 4th quarter. Invesco Ltd. now owns 88,857 shares of the company’s stock worth $2,259,000 after acquiring an additional 12,255 shares in the last quarter. Empowered Funds LLC raised its stake in shares of Immunovant by 4.5% during the fourth quarter. Empowered Funds LLC now owns 14,175 shares of the company’s stock valued at $360,000 after acquiring an additional 610 shares in the last quarter. XTX Topco Ltd boosted its holdings in shares of Immunovant by 91.2% in the fourth quarter. XTX Topco Ltd now owns 33,122 shares of the company’s stock valued at $842,000 after purchasing an additional 15,795 shares during the period. VARCOV Co. purchased a new stake in shares of Immunovant in the fourth quarter valued at approximately $404,000. Finally, Virtus Investment Advisers LLC grew its stake in Immunovant by 41.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,069 shares of the company’s stock worth $256,000 after purchasing an additional 2,931 shares in the last quarter. Institutional investors own 47.08% of the company’s stock.

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.